Improving quality of life in patients with rare autoimmune liver diseases by structured peer-delivered support (Q.RARE.LI): study protocol for a transnational effectiveness-implementation hybrid trial.
Effectiveness-implementation hybrid trial
Liver diseases
Peer-support
Psychosocial support
Psychosomatic medicine
Quality of life
Rare diseases
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
24 03 2023
24 03 2023
Historique:
received:
17
02
2023
accepted:
10
03
2023
medline:
28
3
2023
entrez:
25
3
2023
pubmed:
26
3
2023
Statut:
epublish
Résumé
Psychosocial support is a crucial component of adequate rare disease care, but to date psychosocial support needs of this patient population are insufficiently met. Within Q.RARE.LI, we strive to evaluate the effectiveness of a structured, transdiagnostic, and location-independent psychosocial support intervention in routine care of patients with rare autoimmune liver diseases in five countries and prepare its implementation. Within an effectiveness-implementation hybrid trial, we aim to a) investigate the effectiveness of the intervention in routine care in five diverse healthcare systems and b) assess implementation outcomes, examine and prepare the implementation context, and develop country-specific implementation strategies. To assess effectiveness, we will include N = 240 patients with rare autoimmune liver diseases. Within a two-armed randomized controlled trial (allocation ratio 1:1), we will compare structured and peer-delivered psychosocial support in addition to care-as-usual (CAU) with CAU alone. Outcomes will be assessed via electronic database entry prior to intervention, directly after, and at a three-month follow-up. Our primary effectiveness outcome will be mental health-related quality of life at post-assessment. Secondary outcomes include depression and anxiety severity, perceived social support, helplessness, and disease acceptance. Implementation outcomes will be assessed within a mixed-methods process evaluation. In a quantitative cross-sectional survey, we will examine perceived acceptability and feasibility in patients, peer-counselors, and healthcare providers involved in delivery of the intervention. In qualitative focus groups, we will analyze the implementation context and determine barriers and facilitators for implementation with different stakeholders (patients and/or representatives, peer-counselors, healthcare providers, health insurers). Based on these results, we will derive country-specific implementation strategies and develop a concrete implementation plan for each country. The intervention is expected to help patients adjust to their disease and improve their mental quality of life. The transdiagnostic and location-independent program has the potential to reach patients for psychosocial support who are usually hard to reach. By preparing the implementation in five countries, the project can help to make low-threshold psychosocial support available to many patients with rare diseases and improve comprehensive healthcare for an often neglected group. ISRCTN15030282.
Sections du résumé
BACKGROUND
Psychosocial support is a crucial component of adequate rare disease care, but to date psychosocial support needs of this patient population are insufficiently met. Within Q.RARE.LI, we strive to evaluate the effectiveness of a structured, transdiagnostic, and location-independent psychosocial support intervention in routine care of patients with rare autoimmune liver diseases in five countries and prepare its implementation.
METHODS
Within an effectiveness-implementation hybrid trial, we aim to a) investigate the effectiveness of the intervention in routine care in five diverse healthcare systems and b) assess implementation outcomes, examine and prepare the implementation context, and develop country-specific implementation strategies. To assess effectiveness, we will include N = 240 patients with rare autoimmune liver diseases. Within a two-armed randomized controlled trial (allocation ratio 1:1), we will compare structured and peer-delivered psychosocial support in addition to care-as-usual (CAU) with CAU alone. Outcomes will be assessed via electronic database entry prior to intervention, directly after, and at a three-month follow-up. Our primary effectiveness outcome will be mental health-related quality of life at post-assessment. Secondary outcomes include depression and anxiety severity, perceived social support, helplessness, and disease acceptance. Implementation outcomes will be assessed within a mixed-methods process evaluation. In a quantitative cross-sectional survey, we will examine perceived acceptability and feasibility in patients, peer-counselors, and healthcare providers involved in delivery of the intervention. In qualitative focus groups, we will analyze the implementation context and determine barriers and facilitators for implementation with different stakeholders (patients and/or representatives, peer-counselors, healthcare providers, health insurers). Based on these results, we will derive country-specific implementation strategies and develop a concrete implementation plan for each country.
DISCUSSION
The intervention is expected to help patients adjust to their disease and improve their mental quality of life. The transdiagnostic and location-independent program has the potential to reach patients for psychosocial support who are usually hard to reach. By preparing the implementation in five countries, the project can help to make low-threshold psychosocial support available to many patients with rare diseases and improve comprehensive healthcare for an often neglected group.
TRIAL REGISTRATION
ISRCTN15030282.
Identifiants
pubmed: 36964518
doi: 10.1186/s12888-023-04669-0
pii: 10.1186/s12888-023-04669-0
pmc: PMC10039546
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
193Informations de copyright
© 2023. The Author(s).
Références
von der Lippe C, Diesen PS, Feragen KB. Living with a rare disorder: a systematic review of the qualitative literature. Mol Genet Genomic Med. 2017;5(6):758–73.
pubmed: 29178638
pmcid: 5702559
doi: 10.1002/mgg3.315
EURORDIS. What is a rare disease? Available from: https://www.eurordis.org/informationsupport/what-is-a-rare-disease/ . Accessed 21 Mar 2023.
Uhlenbusch N, Löwe B, Depping MK. Perceived burden in dealing with different rare diseases: a qualitative focus group study. BMJ Open. 2019;9(12)e033353.
pubmed: 31888936
pmcid: 6937088
doi: 10.1136/bmjopen-2019-033353
Uhlenbusch N, Löwe B, Härter M, Schramm C, Weiler-Normann C, Depping MK. Depression and anxiety in patients with different rare chronic diseases: A cross-sectional study. PLoS One. 2019;14(2).
pubmed: 30785907
pmcid: 6382125
doi: 10.1371/journal.pone.0211343
Uhlenbusch N, Swaydan J, Höller A, Löwe B, Depping M. Affective and anxiety disorders in patients with different rare chronic diseases: a systematic review and meta-analysis. Psychol Med. 2021:1–11.
Cohen JS, Biesecker BB. Quality of life in rare genetic conditions: a systematic review of the literature. Am J Med Genet A. 2010;152a(5):1136–56.
Depping MK, Uhlenbusch N, von Kodolitsch Y, Klose HFE, Mautner V-F, Löwe B. Supportive care needs of patients with rare chronic diseases: multi-method, cross-sectional study. Orphanet J Rare Dis. 2021;16(1):44.
pubmed: 33482869
pmcid: 7825171
doi: 10.1186/s13023-020-01660-w
McMullan J, Crowe AL, Bailie C, Moore K, McMullan LS, Shamandi N, et al. Improvements needed to support people living and working with a rare disease in Northern Ireland: current rare disease support perceived as inadequate. Orphanet J Rare Dis. 2020;9(15):315.
doi: 10.1186/s13023-020-01559-6
Uhlenbusch N, Löwe B, Depping M. Perceived burden in dealing with different rare diseases: a qualitative focus group study. BMJ Open. 2019;9(12): e033353.
pubmed: 31888936
pmcid: 6937088
doi: 10.1136/bmjopen-2019-033353
Pimouguet C, Le Goff M, Thiébaut R, Dartigues JF, Helmer C. Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. CMAJ. 2011;183(2):E115–27.
pubmed: 21149524
pmcid: 3033953
doi: 10.1503/cmaj.091786
Song X, Hallensleben C, Zhang W, Jiang Z, Shen H, Gobbens RJJ, et al. Blended self-management interventions to reduce disease burden in patients with chronic obstructive pulmonary disease and asthma: systematic review and meta-analysis. J Med Internet Res. 2021;23(3)e24602.
pubmed: 33788700
pmcid: 8047793
doi: 10.2196/24602
Bryson B, Bogart K, Atwood M, Fraser K, Locke T, Pugh K, et al. Navigating the unknown: A content analysis of the unique challenges faced by adults with rare diseases. J Health Psychol. 2019;26(5):623–35.
pubmed: 30786780
doi: 10.1177/1359105319828150
Eidt D, Frank M, Reimann A, Wagner TOF, Mittendorf T, Graf von der Schulenburg JM. Maßnahmen zur Verbesserung der gesundheitlichen Situation von Menschen mit seltenen Erkrankungen in Deutschland [Measures to improve the health situation of patients with rare diseases in Germany]. Hannover: German Federal Ministry of Health; 2009.
Depping MK, Uhlenbusch N, Löwe B. Acceptance and commitment therapy meets peer-support. Development of a supportive self-care intervention for patients with rare diseases: A multi-stage development process. BMJ Open. accepted.
Depping MK, Uhlenbusch N, Härter M, Schramm C, Löwe B. Efficacy of a brief, peer-delivered self-management intervention for patients with rare chronic diseases. A Randomized Controlled Trial JAMA Psychiatry. 2021;78(6):607–15.
pubmed: 33625502
doi: 10.1001/jamapsychiatry.2020.4783
Bogart KR, Irvin VL. Health-related quality of life among adults with diverse rare disorders. Orphanet J Rare Dis. 2017;12(1):177.
pubmed: 29212508
pmcid: 5719717
doi: 10.1186/s13023-017-0730-1
Jones DEJ, Sturm E, Lohse AW. Access to care in rare liver diseases: New challenges and new opportunities. J Hepatol. 2018;68(3):577–85.
pubmed: 29113911
doi: 10.1016/j.jhep.2017.11.004
Cheung AC, Patel H, Meza-Cardona J, Cino M, Sockalingam S, Hirschfield GM. Factors that influence health-related quality of life in patients with primary sclerosing cholangitis. Dig Dis Sci. 2016;61(6):1692–9.
pubmed: 26743764
doi: 10.1007/s10620-015-4013-1
Janik MK, Wunsch E, Raszeja-Wyszomirska J, Moskwa M, Kruk B, Krawczyk M, et al. Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: A prospective, single-centre study. Liver Int. 2019;39(1):215–21.
pubmed: 30204306
doi: 10.1111/liv.13960
Raszeja-Wyszomirska J, Wunsch E, Krawczyk M, Rigopoulou EI, Bogdanos D, Milkiewicz P. Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis. Liver Int. 2015;35(6):1764–71.
pubmed: 25388280
doi: 10.1111/liv.12730
Raszeja-Wyszomirska J, Wunsch E, Krawczyk M, Rigopoulou EI, Kostrzewa K, Norman GL, et al. Assessment of health related quality of life in polish patients with primary biliary cirrhosis. Clin Res Hepatol Gastroenterol. 2016;40(4):471–9.
pubmed: 26621536
doi: 10.1016/j.clinre.2015.10.006
Arndtz K, Hirschfield GM. Quality of life and primary sclerosing cholangitis: The business of defining what counts. Hepatology. 2018;68(1):16–8.
pubmed: 29315689
doi: 10.1002/hep.29775
Onghena L, Develtere W, Poppe C, Geerts A, Troisi R, Vanlander A, et al. Quality of life after liver transplantation: State of the art. World J Hepatol. 2016;8(18):749–56.
pubmed: 27366301
pmcid: 4921796
doi: 10.4254/wjh.v8.i18.749
Janik MK, Wunsch E, Raszeja-Wyszomirska J, Krawczyk M, Milkiewicz P. Depression: An overlooked villain in autoimmune hepatitis? Hepatology. 2019;70(6):2232–3.
pubmed: 30773711
doi: 10.1002/hep.30568
Schramm C, Wahl I, Weiler-Normann C, Voigt K, Wiegard C, Glaubke C, et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J Hepatol. 2014;60(3):618–24.
pubmed: 24240053
doi: 10.1016/j.jhep.2013.10.035
Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217–26.
pubmed: 22310560
pmcid: 3731143
doi: 10.1097/MLR.0b013e3182408812
Landes SJ, McBain SA, Curran GM. An introduction to effectiveness-implementation hybrid designs. Psychiatry Res. 2019;280:112513.
pubmed: 31434011
pmcid: 6779135
doi: 10.1016/j.psychres.2019.112513
Ware JE Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33 PMID: 8628042.
pubmed: 8628042
doi: 10.1097/00005650-199603000-00003
Depping MK, Uhlenbusch N, Löwe B. Acceptance and commitment therapy meets peer-support. Development of a supportive self-care intervention for patients with rare diseases: a multistage development process. BMJ Open. 2021;11(7):e042856.
Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. Acceptance and Commitment Therapy: Model, processes and outcomes. Behav Res Ther. 2006;44(1):1–25.
pubmed: 16300724
doi: 10.1016/j.brat.2005.06.006
Ware Jr JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Medical care. 1996:220–33.
Ware JE Jr. SF-36 health survey update. Spine. 2000;25(24):3130–9.
pubmed: 11124729
doi: 10.1097/00007632-200012150-00008
Jenkinson C, Layte R, Jenkinson D, Lawrence K, Petersen S, Paice C, et al. A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies? J Public Health. 1997;19(2):179–86.
doi: 10.1093/oxfordjournals.pubmed.a024606
Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. J Clin Epidemiol. 1998;51(11):1171–8.
pubmed: 9817135
doi: 10.1016/S0895-4356(98)00109-7
Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64(2):258–66.
pubmed: 11914441
doi: 10.1097/00006842-200203000-00008
Kroenke K, Spitzer RL, Williams JBW, Löwe B. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345–59.
pubmed: 20633738
doi: 10.1016/j.genhosppsych.2010.03.006
Kroenke K, Spitzer R, Williams W. The patient health questionnaire (PHQ-9)-overview. J Gen Intern Med. 2001;16:606–16.
pubmed: 11556941
pmcid: 1495268
doi: 10.1046/j.1525-1497.2001.016009606.x
Löwe B, Kroenke K, Herzog W, Gräfe K. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). J Affect Disord. 2004;81(1):61–6.
pubmed: 15183601
doi: 10.1016/S0165-0327(03)00198-8
Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.
pubmed: 16717171
doi: 10.1001/archinte.166.10.1092
Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008;46(3):266–74.
pubmed: 18388841
doi: 10.1097/MLR.0b013e318160d093
Evers AWM, Kraaimaat FW, van Lankveld W, Jongen PJH, Jacobs JWG, Bijlsma JWJ. Beyond unfavorable thinking: The Illness Cognition Questionnaire for chronic diseases. J Consult Clin Psychol. 2001;69(6):1026–36.
pubmed: 11777106
doi: 10.1037/0022-006X.69.6.1026
Fydrich T, Geyer M, Hessel A, Sommer G, Brähler E. Social support questionnaire (F-SozU): Norms of a representative sample. Diagnostica. 1999;45(4):212–16. WoS ID: 000083820700006.
Sousa VD, Zauszniewski JA, Bergquist-Beringer S, Musil CM, Neese JB, Jaber AF. Reliability, validity and factor structure of the Appraisal of Self-Care Agency Scale-Revised (ASAS-R). J Eval Clin Pract. 2010;16(6):1031–40.
pubmed: 20626539
doi: 10.1111/j.1365-2753.2009.01242.x
Alberts J, Löwe B, Glahn MA, Petrie K, Laferton J, Nestoriuc Y, et al. Development of the generic, multidimensional Treatment Expectation Questionnaire (TEX-Q) through systematic literature review, expert surveys and qualitative interviews. BMJ Open. 2020;10(8): e036169.
pubmed: 32819942
pmcid: 7440833
doi: 10.1136/bmjopen-2019-036169
Shedden-Mora M, Alberts J, Petrie K, Laferton J, Nestoriuc Y, Löwe B. The treatment expectation questionnaire (TEX-Q)–A generic multidimensional scale measuring patients’ treatment expectations. J Psychosom Res. 2019;121:129–30.
doi: 10.1016/j.jpsychores.2019.03.090
Toussaint A, Murray AM, Voigt K, Herzog A, Gierk B, Kroenke K, et al. Development and validation of the somatic symptom disorder–b criteria scale (SSD-12). Psychosom Med. 2016;78(1):5–12.
pubmed: 26461855
doi: 10.1097/PSY.0000000000000240
Toussaint A, Löwe B, Brähler E, Jordan P. The Somatic Symptom Disorder-B Criteria Scale (SSD-12): factorial structure, validity and population-based norms. J Psychosom Res. 2017;97:9–17.
pubmed: 28606504
doi: 10.1016/j.jpsychores.2017.03.017
Hüsing P, Bassler M, Löwe B, Koch S, Toussaint A. Validity and sensitivity to change of the Somatic Symptom Disorder–B Criteria Scale (SSD-12) in a clinical population. Gen Hosp Psychiatry. 2018;55:20–6.
pubmed: 30232051
doi: 10.1016/j.genhosppsych.2018.08.006
Schwarzer R, Jerusalem M. Generalized Self-Efficacy scale. Measures in health psychology: A user’s portfolio Causal and control beliefs. Windsor, UK: NFER-NELSON; 1995.
Broadbent E, Wilkes C, Koschwanez H, Weinman J, Norton S, Petrie KJ. A systematic review and meta-analysis of the Brief Illness Perception Questionnaire. Psychol Health. 2015;30(11):1361–85.
pubmed: 26181764
doi: 10.1080/08870446.2015.1070851
White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377–99.
pubmed: 21225900
doi: 10.1002/sim.4067
Mayring P. Qualitative content analysis: theoretical foundation, basic procedures and software solution. Klagenfurt. 2014. https://nbn-resolving.org/urn:nbn:de:0168-ssoar-395173 .
Schwartz CE, Sendor RM. Helping others helps oneself: response shift effects in peer support. Soc Sci Med. 1999;48(11):1563–75.
pubmed: 10400257
doi: 10.1016/S0277-9536(99)00049-0
World Health Organization. Patient engagement. Geneva: World Health Organization; 2016.